EP- Patients Objectives Design Methods Introduction Results • • • • • • • • • • • • • • • • • • 17 ECE 17 the at Presented Hormonal values before values Hormonal (%) n adenoma, Typeof (range) member/relative family by Injection self to able Patient Median time since diagnosis, months months diagnosis, since time Median (range) yearsdiagnosis, ageat Median staff healthcare byInjection Male, n (%) n Male, Prior treatment, Prior treatment, n (%) Table 1. Patient demographics and disease characteristics Microadenoma 789-EP the GH patients prescribing included: 90 mg/6 weeks(n=4), 90 mg/8 weeks(n=3), 60mg/8 weeks(n=2) and120 mg/12 weeks(n=1) Five different subgroups were considered for the analysis according to starting dosage pattern. Other dosages Lanreotide with 22 characteristics The 62 The The All Descriptive Patients months, Study into The This Experience Initial Somatostatin requires Control Persistently and Acromegaly with analysis interval with and for,

(95% CI) %ULN IGF of (95% CI) mean ng/mL, GH, Surgery Radiotherapy – – – – Microadenoma Macroadenoma

.

789 8 patients

patients

first

or

levels the

elevated dosage % following decision

administration Lanreotide PAS

To To To To similar . . was

recommended primary refusing

included

of

assess evaluate assess determine

Information Direct (6 of

hormonal study

with

with set whose a

,

the

population GH

<10 mm, mm, <10

reduction <

a

8

Autogel

recommendations provided

statistics

in were 2

elevated - (PAS) intervals

is question question

1, mean and efficacy

active

GH

. to insulin

multicentre,

th were

analogues patients patients’ the and 5 - Spanish

and

inject, n (%) n inject,

are surgery,

a

patients’ objective

European Congress of Endocrinology,EuropeanCongressof Dublin, Ireland,16 Autogel clinical prescribe 18 9 5 1 Azpiroz Escolá Álvarez Cristina practice clinical routine in acromegalypatients initial with control hormonal achieve to ACROSTART: Spanish retrospective study determine to the timeframe Virgen de las Nieves,Virgende las Granada; Rabinovich Elena María Torres Vela

ng/mL

adults

use

on dose omission and on whether the patient was continuing continuing was patient the on whether and omission on dose Hospital Universitario Hospital UniversitarioPrincesa,La Madrid;de Hospital Universitario La Paz, Madrid; efficacy rare levels

12 macroadenoma screened IPSEN

response

it

because

shown

treatment IGF by secondary 120

about about acromegaly

- of was

.

in weeks) Cristina Álvarez Escolá Pituitary clinical

like

doses written summarized 5 , GH of adherence

consisted

healthcare close

chronic

general -1 Starting managed GH

hospitals

and/or records

with

< after mg Lanreotide of

and

satisfactionpossible 3 answers with satisfied(verysatisfied, all satisfied, at not

growth

prescribed

2 Pharma

(SSAs)

and secretion

Lanreotide Lanreotide in was .

non 5 levels

of was

from

available

they 5

relatives informed reported active Table achieving ng/mL failure

, MaríaÁngeles Gálvez Moreno satisfaction

IGF >10 mm. PAS, Primary Analysis Set. Analysis PAS,Primary mm. >10

objectives -interventional, normalised

endocrine to the

resources lacked

conducted dose

factor to

the

indicated of

Lanreotide underwent , injections have 08

to -I

quantitative 15

L’Hospitalet

(8.1; 325.5) (13.0; 77.0) SSA

1

Autogel

acromegaly is Autogel 57 and/or

levels of (1.6; 2.1) 22 (38.6) (2.6; 7.4) 35 (61.4) 44 (77.2) 21 (36.8) 39 (68.4) 14 (24.6) 1.9xULN

< according determine

8 (14.0) most

March

, Concepción, Páramo Fernández 5 (8.8)

103.5

N=57 2 Autogel

in were PAS – consent decisive

surgical 5.0

for

51 . hormonal information I Germans become patients 5

with

Lanreotide 44

until (IGF

:

ng/mL

disease,

common

lead Lanreotide

Autogel that

in % IGF

normalised

excluded at

Lanreotide commonly

without to

obtaining surgery controlling

-I)

of

17 was

variables

-1 to 31 treatment, in de Llobregat, retrospective,

a

to

(14.6; 285.0) the levels, and the (26.0; 74.0)

the who 14

with

longer centres

control Trias routine

10 (76.9) (1.4; 2.2) (0.7; 7.6 improving 4 weeks 1.8xULN therapy on substantial 2 (15.4) 8 5 4 ( 8 ( 2 (

Hospital ClínicoCarlos, San Madrid; October 60 mg/

1 (7.7) made 100.7

n=13 regarding

characterized 55.0

dose ( (

A patients 4.2

61.5) 38.5) 30.8) 61.5) assistance

15.4) pillar

normalisation

hormonal or utogel ≥ Autogel

1

timeframe a had tumour

2

Autogel

11 IGF , MaríaVenegas Eva Moreno i Pujol, Badalona;i used

the

received

2

median dosage

consecutive

)

Hospital Universitario Virgen Rocío,del Sevilla;

clinical

prior

to

in , María, Ángeles Gonzalo Redondo

or

of

- been

most

2013 1

Spain

start

are therapy survival, size in in

acromegaly

Spain levels control the morbidity (−11.3; 37.5)

(8.1; 128.4) (21.0; 76.0) post

to clinical selected

(1.7; 5.0) 4 weeks 3.3xULN treatmentat the end of the study

2 (33.3) 4 (66.7) 1 ( 5 ( 2 ( prescribed

90 mg/

2 4 of

60 6

interval

in

. 103.7 20 May 2015 May -20 practice frequent

age treatment treated radiotherapy Hospital Universitario Reina Sofía,Córdoba; 13.1 and

45.0

n=6 date ( (

16.7) 83.3) 33.3)

to

Five by 33.3) 66.7)

0 daily

- , healthcare of

authorisation

on 90

3

enhanced

independently

IGF evaluations of

achieve

and

practice

and

clinical patients at and

and

cases

could

64

with -

10 cause least medical 1

optimum initial (19.3; 284.2) Hospital de la SantaHospital de

(51

(20.0; 77.0) in 120 mortality levels (0.2; 13.4

years 10 (76.9) (1.2; 2.1) 4 weeks 1.6xULN

120 mg/

practice 2 (15.4) 6 ( 7 ( 6 (

6 7

1 (7.7)

129.9 n=13

Lanreotide

between be staff, 49.0 % as clinical ( ( two

6.8

46.2) 53.8) 46.2)

46.2) 53.8) hormonal were growth

mg of

6

dose

)

patients), used

3 primary

study , Edelmiro MenéndezEdelmiro, Torre

therapy

considering

which (range

consecutive

administered )

either management from ) 2

excluded

of

practice

in

the 15 hormone

(17.9; 325.5)

performed

Lanreotide

(13.0; 72.0)

is Hospital

the well

treatment

(0.8; 1.8) 16 (0.6; 3.2 Autogel 6 weeks 1.3xULN 120 mg/

5 (83.3) 1 (16.7) 3 ( 4 ( 1 ( 23

in 6 with

control with initiation 170.1 a 51.0 n=6 ( 1.9

, Antonio Miguel Picó AlfonsoPicó Miguel, Antonio

50.0) 66.7) 16.7)

100) -90 0 patient's pituitary patients 0 controlled

the

from

self evaluations extended Creu may

)

)

.

(GH)

every

Clínic of

for Demographic

starting -injections 4

(defined

in

Autogel of the the

i 2 differ

(41.6; 218.6) adenoma unsuitable

(34.0; 72.0) enrolment

at Sant treatment , Juan Antonio García Arnés

secretion (1.0; 2.2) (1.3; 5.3 8 weeks 1.6xULN 62 120 mg/

28

2 3 ( 7 (

1 (11.1) 9 (100) 7

Provincial, Barcelona; disease patients 120.8 primary 3

47.0 least n=9 ( dosing Hospital Regional Universitario Carlos Haya, Málaga; ( 3.3 22.2) 33.3) 77.8)

77.8) 0 0

days

dose adult

Pau, Barcelona; from

and DOI: 10.3252/pso.eu.17ece.2015

as

7

)

or

Hospital UniversitarioHospitalde Asturias, Oviedo; Central

4 1 .

12

, Ricardo, VílchezJoya endpoints Secondary Primary endpoint • • • • • • mean(95% CI) 2. Figure Set. Analysis Primary PAS, 1. Figure *Informationnot wasavailable 2patients.for Autogel 3. Figure Set. Analysis Primary PAS, References for The Globally, Mean There treatment Globally, At patients 2. 3. 1. Mean number (95% CI)

• • •

10 Patients (%) 100 Months the the 11 10 12 14 16 18 20 7 0 1 2 3 4 5 6 7 8 9 10 20 30 40 50 60 70 80 90 Conclusions

Manjila Reddy Reddy Holdaway 0 2 4 6 8 use 0 , Javier Aller Pardo AllerJavier , Lanreotide responder Real One In being despite Hospital Universitario Cecilio,San Granada;

16

length

was beginning 24

Complejo Hospitalario Endocrinologist visits Endocrinologist therapy

a

with of Use of healthcare resources until hormonal control in the PAS population (N=57), number, (N=57), PAS population in the control hormonal until resources healthcare of Use months control, to time hormonal Median Patient satisfaction with with satisfaction Patient the

R, et al. et R,

51

Not at all

S, et al. et S, (1.2, 117.0) patients at -

fifth a real life healthcare

IM, et al. et IM, PAS

the the

N=57 L 4.9 median very 7.3 of out available

disparity

treatment

BMJ BMJ (4.2, 9.9) -

Neurosurg

end of

(n=55)* treatment

anreotide anreotide life

most 17 of of 7.1

good

with

patients,

Eur

Autogel

2010; 341:c4189. the treatment, , Sara ArroyoSara ,

55 of

time

setting, J presented

resources

information, available the Endocrinol

adherence

(92 common

patients Satisfied Focus

with Poster to 3

of 41.8 (1.2, 57.6) study 60 mg/ 60 , Concepción, Carrera Blanco .

4 wks 7 reach

5.0 n=13 at:

13 %

starting 2010;29:E14. Xeral

and with Lanreotide the with

)

2008;159(2):89 , MaríaPaz deMiguel Novoa

the information

until (Figure patients

mean Laboratory tests

hormonal

to 8

managed Lanreotide Lanreotide -Cies

and achieving starting

,Salinas IsabelVert

Lanreotide

therapy a reaching median 4

satisfied

Hospital Universitario Príncipe deAsturias,Henares; Alcalá de

(3.1, 5.4) doses high

it 8

18

Very maximum de Vigo, Vigo;

Hospital Universitario Hierro,Puertade Majadahonda; 50.9 3 Autogel

4.2 rated was ) (2.6, 28.3) Starting dosage of Lanreotide Lanreotide of dosage Starting

90 mg/ 90 – , Francesc Pérez Francesc ,

4 wks

95 control

3.4 (Figure

n=6 A .

dose

treatment

hormonal 1139

injections

time and to

hormonal 12 was utogel

Fundación Jiménez Díaz,Madrid;

be tumour

was 5. 4. Autogel

mm

4

(range) interval

68 Lucas Giustina ) elapsed satisfied 17

P AS, Primary Analysis Set. Analysis Primary PAS, (N=57 PAS population 4. Figure

3 4

control Hospital General

months . (95 9

(2.2, 106.8) 120 mg/

volume T, al. et

adherence 4 wks without Imaging tests Imaging months

Patients (%) 100

A. et al. et A.

% n=13 10 20 30 40 50 60 70 80 90 8.1

control 0

led

dosing CI (1.3, 2.3) is or

(95 Clin

1.8 between Patient adherence to treatment

shown No doses missed 0

was Nat. Rev. Rev. Nat. 9 very

(range ,

% , Eugenia, Resmini Endocrinol to

3185 18 assistance treatment in treatment

CI

was 2010

satisfied a

, Pineda Eva

4

in 86.0 55 and , Mónica

Universitari Endocrinol

) (2.8, 117.0) 120 mg/ 1

Autogel fast Figure

6 wks at

-80 .

( 2 8.2 mm initiating Oxf 4 14 n=6

,

last

. ) 117 ) 9 treatment ) , Irene

2006;65(3):

3 Absenteeism days Funding byFunding with hormonal

months

(95 2014;10:243 evaluation

. 2

0 of

13 )

% d'Alacant (Figure Hospital General

the healthcare (9.2, 27.1)

Marazuela

CI 18.1 treatment 320

Halperín 120 mg/ Lanreotide (1.8, 22.0) Continuing

0 Ipsen 8 wks treatment – with – 18 satisfaction, , 248.

326.

4.2

n=9 during 5774 1 82.5

, Alacant;

control )

10 Pharma, Spain.

120

in the in the

) ,

for treatment staff

with Autogel

mg the

in

19